Reports Q1 revenue $1.176B, consensus $372.61M. Total revenue also includes royalty, collaboration and license, and manufacturing revenue of $1.022.7B, compared to $32.5M last year. “Following a year of outstanding execution across every part of the Company, we have built on this positive momentum with solid revenue performance in the first quarter, allowing us to narrow our full-year revenue guidance,” said Matthew B. Klein, CEO. “Our strong cash balance supports all of our planned commercial and R&D activities and provides the ability to reach cashflow breakeven without raising additional capital. The positive CHMP opinion for Sephience kickstarts our anticipated global launch for what we see as a significant revenue opportunity.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Optimistic Buy Rating for PTC Therapeutics Amid Market Skepticism and Promising Stage 2 Data
- Hold Rating for PTC Therapeutics Amid Mixed Clinical Results and Uncertain FDA Approval Prospects
- PTC Therapeutics price target lowered to $57 from $65 at RBC Capital
- PTC data ‘brought more confusion than answers,’ says Citi